ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy

Table 2 Clinicopathologic characteristics and treatment outcomes of ALK-rearranged patients

Case	Age	Sex	Stage	SS	IHC	FISH	RT-PCR	Treatment	Outcome	Status
1	60	F	I	NS	+	Fail	Fail	Surgical resection + adjuvant CMT	CR	Alive
2	69	F	I	NS	+	Fail	+	Surgical resection	CR	Alive
3	56	F	I	NS	+	Fail	+	Surgical resection + adjuvant CMT	CR	Alive
4	41	F	I	NS	+	+	+	Surgical resection	CR	Alive
5	69	F	I	NS	+	+	+	Surgical resection	CR	Alive
6	43	F	II	NS	+	+	+	Surgical resection + adjuvant CMT	CR	Alive
7	47	F	II	NS	+	+	+	Surgical resection + adjuvant CMT	CR	Alive
8	62	F	IV	NS	+	+	+	Lost to follow-up	NA	Alive
9	45	M	IV	NS	+	−	+	Best palliative care	PD	Death
10	51	M	IV	NS	+	+	+	CMT + WBRT	PR	Death
11	43	F	IV	NS	+	Fail	−	Surgical resection + CMT + WBRT	PR	Death
12	40	F	IV	NS	+	+	+	Surgical resection + RT	PR	Death
13	63	F	I	NS	+	+	+	Surgical resection + CMT + third-line crizotinib	PR	Alive
14	71	F	I	NS	+	+	+	Surgical resection + CMT + fourth-line crizotinib then ceritinib	PR	Alive
15	63	F	II	NS	+	+	+	Surgical resection + CMT + second-line crizotinib	PR	Alive
16	49	M	III	NS	+	+	+	First-line crizotinib	PR	Alive
17	61	F	III	NS	+	+	+	CMT + third-line crizotinib	CR	Alive
18	69	M	IV	NS	+	+	+	CMT then third-line crizotinib	PR	Alive
19	27	F	IV	NS	+	+	+	First-line crizotinib then ceritinib	PR	Alive
20	61	F	IV	NS	+	+	+	CMT + second-line crizotinib	PR	Alive
21	74	M	IV	SM	+	+	+	CMT + second-line crizotinib	PR	Alive
22	61	F	IV	NS	+	+	−	CMT + second-line crizotinib	SD	Death
23	90	M	IV	SM	+	+	+	First-line crizotinib	PR	Death
24	40	F	IV	NS	+	+	+	CMT + third-line crizotinib	PR	Death
25	38	F	IV	NS	+	+	+	CMT + third-line crizotinib	PR	Death
26	24	F	IV	NS	+	NA	+	First-line crizotinib	PR	Death

Abbreviations: SS smoking status, NS non-smoker, SM smoker, CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not available

ISSN: 1477-7819